Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 21

1.

Response to the Letter-to-the Editor by Cohen et al. concerning our eNeurologicalSci article, Melamed-Gal, et al. Physicochemical, biological, functional and toxicological characterization of the European follow-on glatiramer acetate product as compared with Copaxone. eNeurologicalSci 2018;12:19-30.https://doi.org/10.1016/j.ensci.2018.05.006.

Melamed-Gal S, Loupe P, Timan B, Weinstein V, Kolitz S, Zhang J, Funt J, Komlosh A, Ashkenazi N, Bar-Ilan O, Konya A, Beriozkin O, Laifenfeld D, Hasson T, Zeskind B, Hayden M, Nock S, Grossman I.

eNeurologicalSci. 2018 Nov 28;13:53-55. doi: 10.1016/j.ensci.2018.11.007. eCollection 2018 Dec. No abstract available.

2.

Physicochemical, biological, functional and toxicological characterization of the European follow-on glatiramer acetate product as compared with Copaxone.

Melamed-Gal S, Loupe P, Timan B, Weinstein V, Kolitz S, Zhang J, Funt J, Komlosh A, Ashkenazi N, Bar-Ilan O, Konya A, Beriozkin O, Laifenfeld D, Hasson T, Krispin R, Molotsky T, Papir G, Sulimani L, Zeskind B, Liu P, Nock S, Hayden MR, Gilbert A, Grossman I.

eNeurologicalSci. 2018 May 30;12:19-30. doi: 10.1016/j.ensci.2018.05.006. eCollection 2018 Sep.

3.

Large-scale transcriptomic analysis reveals that pridopidine reverses aberrant gene expression and activates neuroprotective pathways in the YAC128 HD mouse.

Kusko R, Dreymann J, Ross J, Cha Y, Escalante-Chong R, Garcia-Miralles M, Tan LJ, Burczynski ME, Zeskind B, Laifenfeld D, Pouladi M, Geva M, Grossman I, Hayden MR.

Mol Neurodegener. 2018 May 21;13(1):25. doi: 10.1186/s13024-018-0259-3.

4.

Compositional differences between Copaxone and Glatopa are reflected in altered immunomodulation ex vivo in a mouse model.

Grossman I, Kolitz S, Komlosh A, Zeskind B, Weinstein V, Laifenfeld D, Gilbert A, Bar-Ilan O, Fowler KD, Hasson T, Konya A, Wells-Knecht K, Loupe P, Melamed-Gal S, Molotsky T, Krispin R, Papir G, Sahly Y, Hayden MR.

Ann N Y Acad Sci. 2017 Nov;1407(1):75-89. doi: 10.1111/nyas.13547.

PMID:
29168242
5.

A pharmacogenetic signature of high response to Copaxone in late-phase clinical-trial cohorts of multiple sclerosis.

Ross CJ, Towfic F, Shankar J, Laifenfeld D, Thoma M, Davis M, Weiner B, Kusko R, Zeskind B, Knappertz V, Grossman I, Hayden MR.

Genome Med. 2017 May 31;9(1):50. doi: 10.1186/s13073-017-0436-y.

6.

Drug repurposing from the perspective of pharmaceutical companies.

Cha Y, Erez T, Reynolds IJ, Kumar D, Ross J, Koytiger G, Kusko R, Zeskind B, Risso S, Kagan E, Papapetropoulos S, Grossman I, Laifenfeld D.

Br J Pharmacol. 2018 Jan;175(2):168-180. doi: 10.1111/bph.13798. Epub 2017 May 18. Review.

7.

Letter to the Editor response: Nygaard et al.

Towfic F, Kusko R, Zeskind B.

Biostatistics. 2017 Apr 1;18(2):197-199. doi: 10.1093/biostatistics/kxw031.

8.

Pridopidine activates neuroprotective pathways impaired in Huntington Disease.

Geva M, Kusko R, Soares H, Fowler KD, Birnberg T, Barash S, -Wagner AM, Fine T, Lysaght A, Weiner B, Cha Y, Kolitz S, Towfic F, Orbach A, Laufer R, Zeskind B, Grossman I, Hayden MR.

Hum Mol Genet. 2016 Sep 15;25(18):3975-3987. doi: 10.1093/hmg/ddw238. Epub 2016 Jul 27.

9.

Pharmacogenomics strategies to optimize treatments for multiple sclerosis: Insights from clinical research.

Grossman I, Knappertz V, Laifenfeld D, Ross C, Zeskind B, Kolitz S, Ladkani D, Hayardeny L, Loupe P, Laufer R, Hayden M.

Prog Neurobiol. 2017 May;152:114-130. doi: 10.1016/j.pneurobio.2016.02.001. Epub 2016 Mar 4. Review.

PMID:
26952809
10.

Functional effects of the antigen glatiramer acetate are complex and tightly associated with its composition.

Hasson T, Kolitz S, Towfic F, Laifenfeld D, Bakshi S, Beriozkin O, Shacham-Abramson M, Timan B, Fowler KD, Birnberg T, Konya A, Komlosh A, Ladkani D, Hayden MR, Zeskind B, Grossman I.

J Neuroimmunol. 2016 Jan 15;290:84-95. doi: 10.1016/j.jneuroim.2015.11.020. Epub 2015 Nov 24.

11.

Rates of Adverse Events and Multiple Sclerosis Relapses Before and After Introduction of a Purported Generic Glatiramer Acetate in mexico: Results from a Large Patient Support Program in Mexico.

Ramirez D, Flores J, Verdi D, Gandhi S, Grossman I, Zeskind B, Grinspan A.

Value Health. 2015 Nov;18(7):A877. doi: 10.1016/j.jval.2015.09.050. Epub 2015 Oct 20. No abstract available.

12.

Leveraging existing data sets to generate new insights into Alzheimer's disease biology in specific patient subsets.

Fowler KD, Funt JM, Artyomov MN, Zeskind B, Kolitz SE, Towfic F.

Sci Rep. 2015 Sep 23;5:14324. doi: 10.1038/srep14324.

13.

Gene expression studies of a human monocyte cell line identify dissimilarities between differently manufactured glatiramoids.

Kolitz S, Hasson T, Towfic F, Funt JM, Bakshi S, Fowler KD, Laifenfeld D, Grinspan A, Artyomov MN, Birnberg T, Schwartz R, Komlosh A, Hayardeny L, Ladkani D, Hayden MR, Zeskind B, Grossman I.

Sci Rep. 2015 May 22;5:10191. doi: 10.1038/srep10191.

14.

Use of genetic technologies to compare medicines.

Kolitz SE, Towfic F, Grossman I, Hayden MR, Zeskind B.

Clin Genet. 2014 Nov;86(5):441-6. doi: 10.1111/cge.12462. Epub 2014 Sep 8. Review.

PMID:
25046029
15.

Comparing the biological impact of glatiramer acetate with the biological impact of a generic.

Towfic F, Funt JM, Fowler KD, Bakshi S, Blaugrund E, Artyomov MN, Hayden MR, Ladkani D, Schwartz R, Zeskind B.

PLoS One. 2014 Jan 8;9(1):e83757. doi: 10.1371/journal.pone.0083757. eCollection 2014.

16.

Lebrikizumab treatment in adults with asthma.

Zeskind B.

N Engl J Med. 2011 Dec 22;365(25):2432; author reply 2433-4. doi: 10.1056/NEJMc1112234. No abstract available.

PMID:
22187992
17.

IL-6 and ovarian cancer--letter.

Locasale JW, Zeskind B.

Clin Cancer Res. 2011 Dec 15;17(24):7837; author reply 7838. doi: 10.1158/1078-0432.CCR-11-2170. Epub 2011 Dec 6. No abstract available.

18.

Maximizing the efficacy of angiogenesis inhibitors.

Locasale JW, Zeskind BJ.

J Clin Oncol. 2012 Jan 20;30(3):337-8; author reply 338-9. doi: 10.1200/JCO.2011.38.5435. Epub 2011 Dec 5. No abstract available.

PMID:
22147743
19.

Emerging concepts in biomarker discovery; the US-Japan Workshop on Immunological Molecular Markers in Oncology.

Tahara H, Sato M, Thurin M, Wang E, Butterfield LH, Disis ML, Fox BA, Lee PP, Khleif SN, Wigginton JM, Ambs S, Akutsu Y, Chaussabel D, Doki Y, Eremin O, Fridman WH, Hirohashi Y, Imai K, Jacobson J, Jinushi M, Kanamoto A, Kashani-Sabet M, Kato K, Kawakami Y, Kirkwood JM, Kleen TO, Lehmann PV, Liotta L, Lotze MT, Maio M, Malyguine A, Masucci G, Matsubara H, Mayrand-Chung S, Nakamura K, Nishikawa H, Palucka AK, Petricoin EF, Pos Z, Ribas A, Rivoltini L, Sato N, Shiku H, Slingluff CL, Streicher H, Stroncek DF, Takeuchi H, Toyota M, Wada H, Wu X, Wulfkuhle J, Yaguchi T, Zeskind B, Zhao Y, Zocca MB, Marincola FM.

J Transl Med. 2009 Jun 17;7:45. doi: 10.1186/1479-5876-7-45.

20.

A systematic approach to biomarker discovery; preamble to "the iSBTc-FDA taskforce on immunotherapy biomarkers".

Butterfield LH, Disis ML, Fox BA, Lee PP, Khleif SN, Thurin M, Trinchieri G, Wang E, Wigginton J, Chaussabel D, Coukos G, Dhodapkar M, HÃ¥kansson L, Janetzki S, Kleen TO, Kirkwood JM, Maccalli C, Maecker H, Maio M, Malyguine A, Masucci G, Palucka AK, Potter DM, Ribas A, Rivoltini L, Schendel D, Seliger B, Selvan S, Slingluff CL Jr, Stroncek DF, Streicher H, Wu X, Zeskind B, Zhao Y, Zocca MB, Zwierzina H, Marincola FM.

J Transl Med. 2008 Dec 23;6:81. doi: 10.1186/1479-5876-6-81.

Supplemental Content

Loading ...
Support Center